ISRCTN ISRCTN29665319
DOI https://doi.org/10.1186/ISRCTN29665319
Clinical Trials Information System (CTIS) 2009-016731-34
Protocol serial number EME 08/99/04; CRO1413
Sponsor Imperial College London (UK)
Funder Medical Research Council (MRC)/National Institutes of Health Research (NIHR) (UK) - Efficacy and Mechanism Evaluation (EME) Programme (ref: EME 08/99/04)
Submission date
28/10/2009
Registration date
25/11/2009
Last edited
04/05/2016
Recruitment status
No longer recruiting
Overall study status
Completed
Condition category
Pregnancy and Childbirth
Prospectively registered
Protocol
Statistical analysis plan
Results
Individual participant data

Plain English summary of protocol

Not provided at time of registration

Contact information

Dr Sabita Uthaya
Scientific

Chelsea and Westminster Hospital
3rd Floor
Lift bank B
369 Fulham Road
London
SW10 9NH
United Kingdom

Study information

Primary study designInterventional
Study designMulticentre randomised 2 x 2 factorial double-blind controlled trial
Secondary study designRandomised controlled trial
Study type Participant information sheet
Scientific titleAmino acid regimen and intravenous lipid composition in preterm parenteral nutrition: a randomised controlled trial of Nutritional Evaluation and Optimisation in Neonates
Study acronymNEON
Study objectivesIntroduction of recommended daily intake (RDI) of amino acids will lead to an increase in non-adipose (lean) body mass; administration of SMOFLIPID® will reduce intrahepatocellular lipid content (IHCL) in preterm babies at term age equivalent.

Link to EME project website: http://www.eme.ac.uk/projectfiles/089904info.pdf
Protocol can be found at: http://www.eme.ac.uk/projectfiles/089904protocol.pdf
Ethics approval(s)Hammersmith Research Ethics Committee, 08/12/2009
Health condition(s) or problem(s) studiedPreterm birth
InterventionEligible preterm infants will be randomised by 24 hours of age (previously 12 hours of age, updated 02/07/2013) to receive:
1. Either incremental amino acids in parenteral nutrition or the RDI of amino acids from day one, and
2. Either 20% intralipid or 20% SMOFLIPID®

There will be four groups:
Group 1: incremental amino acid and 20% intralipid
Group 2: incremental amino acid and 20% SMOFLIPID®
Group 3: RDI of amino acids and 20% intralipid
Group 4: RDI of amino acids and 20% SMOFLIPID®

Infants will be followed from birth and until they reach 37 - 44 weeks corrected age at which point the final study assessment (magnetic resonance imaging [MRI] scan) takes place.
Intervention typeSupplement
Primary outcome measure(s)

1. For the amino acid intervention: non-adipose (lean) body mass measured by whole body MRI at term age equivalent
2. For the lipid intervention: hepatic magnetic resonance spectroscopy (MRS) to measure IHCL at term age equivalent

Key secondary outcome measure(s)

1. Anthropometry (weight, length and head circumference) measured at term age equivalent
2. Brain MRI (brain volumes, white matter apparent diffusion co-efficient values, cerebral vessel tortuosity) measured at term age equivalent
3. Metabolic index of insulin resistance at term age equivalent (quantitative insulin-sensitivity check index [QUICKI]), calculated using fasting serum glucose and insulin

Added 07/12/2009:
4. Ratio of internal to subcutaneous adipose tissue at term age equivalent.
5. Serum triglyceride and serum bilirubin levels.

Added 11/05/2010:
6. Metabonomic profile
7. Incidence of death
8. Number of infants with incomplete follow-up

Added 24/03/2011:
9. Inflammatory markers and lipid profile

Completion date31/12/2013

Eligibility

Participant type(s)Patient
Age groupNeonate
SexAll
Target sample size at registration160
Key inclusion criteria1. Preterm infants (either sex) born below 31 weeks of gestation (defined as less than or equal to 30 weeks and 6 days)
2. Written informed consent from parents
Key exclusion criteria1. Major congenital or life threatening abnormalities
2. Inability to randomise in time to allow administration of trial parenteral nutrition (PN) within 24 hours of birth
Date of first enrolment20/05/2010
Date of final enrolment31/12/2013

Locations

Countries of recruitment

  • United Kingdom
  • England

Study participating centre

Chelsea and Westminster Hospital
London
SW10 9NH
United Kingdom

Results and Publications

Individual participant data (IPD) Intention to shareNo
IPD sharing plan summaryNot provided at time of registration
IPD sharing plan

Study outputs

Output type Details Date created Date added Peer reviewed? Patient-facing?
Results article results 01/03/2016 Yes No
Results article results 01/06/2016 Yes No
Participant information sheet Participant information sheet 11/11/2025 11/11/2025 No Yes
Study website Study website 11/11/2025 11/11/2025 No Yes

Editorial Notes

21/04/2016: Publication reference added.
01/04/2016: Publication reference added.
11/05/2010: the overall trial start and end dates were changed from 10/01/2010 and 31/07/2013 to 20/05/2010 and 31/12/2013, respectively.